1989 VALUATION ACTUARY SYMPOSIUM PROCEEDINGS

REGULATOR PANEL - CANADIAN

The following is meant as a summary of the presentations and discussions occurring at the "Regulator Panel" held on September 14, 1989, at the Valuation Actuary Symposium in Philadelphia.

The session started by Mr. Muirhead-Gould's preliminary comments and introduction of the panelists.

Then Mr. Andre L'Esperance, Chief of the Actuarial Section, Life Division of the Office of the Superintendent of Financial Institutions (OSFI), summarized the highlights of the first report produced by OSFI regarding the reporting and valuation practices used by the companies for the provision for AIDS. Such a report is available upon request at OSFI's offices. Slides 1 through 7 are copies of the overheads used by Mr. L'Esperance for that presentation.

Mr. L'Esperance then summarized the preliminary findings from the analysis of the special reports filed by companies regarding the impact of the proposed Policy Premium Method

(PPM) as the new valuation standard. Slides 8 through 15 are copies of the overheads used by Mr. L'Esperance for his presentation.

Mr. L'Esperance's presentation of the preliminary statistical results about the Policy Premium Method was followed by observations and comments from Mr. Donald McIsaac, Director General of the Life Division of OSFI.

General Background

Mr. McIsaac mentioned that OSFI relied in the past on the quinquennial exams supplemented by the review of the annual valuation actuary reports. OSFI has found that such "quins" have become less relevant because of increased complexity in the valuation process, the wide discretion in the choice of the assumptions and the existing backlog where a stale-dated "quin" is of little help. OSFI's reliance on a desk review of valuation actuary reports is not effective and only serves to identify the problems "flagged" by the actuary; therefore the valuation actuary reports need more intense study since reliance on monitoring has been done in comparison to the peer group. Auditors and company management depend upon OSFI's scrutiny. Therefore OSFI had to revise its approach and apply its resources to a real-time monitoring using the valuation actuary reports as a tool while establishing face-to-face contact with the valuation actuaries. OSFI should have a look at the actuary's working papers and the examination should be completed in a more

timely fashion than has been the case for quinquennial examinations: such conclusions would develop a need for more actuaries in OSFI. Accordingly OSFI retained the services of Mr. Bill Wilson as a consultant, whose mandate was to focus on the aforementioned activities. Mr. Wilson's recommendations have been given to OSFI, one of which is the creation of new positions.

At this point, Mr. McIsaac introduced the new "Director of the Actuarial Section," Mr. Narinda Handa, who will be located in the Toronto Office. Valuation actuaries can expect to see him and his colleagues in the not so distant future although it is likely to take some time to put the reorganization fully into place.

Comments Regarding the Special Report

Reports have been scrutinized (which means that the work related to quinquennial exams has been set aside). Databases have been created, and the reports have been analyzed through a written review. A fair number of them have gone through a second reading stage where all reports have been scrutinized by at least one qualified Fellow. The review of the reports is not yet completed since a few more reports are expected to come; submissions so far have not really set aside all our fears, and therefore, OSFI is not comfortable at this point to make a final recommendation. OSFI feels that it needs help in dealing with the findings, more specifically for the sensitivity issue where a particular problem appears

to exist. The results of OSFI's survey indicate no great reserve change when expressed as a percentage of liabilities, but the large increase in appropriated surplus is cause for concern in light of the direction of the discussions relating to capital adequacy, or the Minimum Continuing Capital Surplus Requirement (MCCSR).

OSFI is somewhat disturbed by the disregard for CIA valuation standards as seems to be reflected in the statistics on compliance. The front-ending of profits issue is probably not going to be a concern although it is unclear how OSFI should interpret the selection of assumptions since it appears that some actuaries were able to choose assumptions in such a manner as to predict whether or not products will show front-ending of profits.

Participating insurance is a domain which requires work; there appears to be some confusion about the appropriate valuation standard; sharp reductions in reserves were observed for a number of companies submitting participating insurance data in their special reports. OSFI does not see how GAAP can be successfully implemented without standards or controls in this area. It may well be OSFI should retain a limit on deferred acquisition expenses for participating insurance business.

The results of the sensitivity study are alarming: some testing showed PPM reserves to be 300% more sensitive to changes in assumptions than the current method; a look at the constraints regarding the selection of assumptions is required.

Looking to the future it seems evident that OSFI will authorize the new method and make it work for all lines. However, there are a number of remaining issues to be resolved if the implementation of GAAP is to be successful for all the business lines. There is a clear need for valuation standards for participating insurance. At the same time a formal approval process has to be established to ensure that OSFI accepts valuation technique papers as standards for use by all actuaries. OSFI may have to be prepared to set down criteria for some important issues: one example is the provision for future expenses. The changes in assumptions will need more disclosure in future valuation actuary reports, and the Superintendent and his staff may question actuaries more aggressively on their choice of assumptions. Perhaps OSFI will need increased consultation with the Institute's Review Committee.

AIDS - A REPORT ON COMPANY VALUATION PRACTICES FOR 1988 YEAR-END

INTRODUCTION

SCOPE OF ANALYSIS

REPORTING FOR AIDS:

- GENERAL
- EXPLICIT
- IMPLICIT

1988 AIDS EXPLICIT PROVISIONS:

- PER AMOUNT IN FORCE
- AS A PERCENTAGE OF CAPITAL AND UNAPPROPRIATED SURPLUS
- AS A PERCENTAGE OF LIABILITIES

SUPPLEMENTAL BREAKDOWNS

APPENDICES

1988 AIDS PROVISION

SCOPE OF ANALYSIS


FEDERALLY REGISTERED LIFE INSURANCE COMPANIES

UMBER OF VALUATION ACTUARY'S REPORTS REVIEWED:				
REPORTED ON THE PROVISIONING FO	DR AIDS:			
CANADIAN COMPANI	IES:	56		
BRITISH COMPANIES	:	10		
FOREIGN COMPANIE	S:	_74		
	TOTAL:	140		

ESTIMATED PROVISION FOR AIDS SET FOR 1988 YEAR-END PURPOSES BY ALL FEDERALLY REGISTERED COMPANIES

TYPE OF PROVISION	AMOUNT (\$MILLION)
EXPLICIT	\$379
IDENTIFIED IMPLICIT	\$ 110
OTHER	<u>\$ 61</u>
TOTAL	\$550

1988 PROVISION AMOUNTS FOR AIDS FEDERALLY REGISTERED LIFE INSURANCE CO.



CLASSIFICATION OF COMPANIES FOR PURPOSES OF THE REPORT

<u>CANADIAN COMPANIES</u> = ACCORDING TO <u>TOTAL ASSETS</u>

<u>BRITISH AND FOREIGN COMPANIES</u> = ACCORDING TO <u>CANADIAN</u>

<u>LIABILITIES</u>

"SMALL" = < \$200 MILLION

"MEDIUM" = ≥ \$200 MILLION AND ≤ \$4 BILLION

"LARGE" = > \$ 4 BILLION

1988 AIDS EXPLICIT PROVISIONS

FEDERALLY REGISTERED LIFE INSURANCE COMPANIES

PROVISION PER \$1,000 INDIVIDUAL LIFE INSURANCE IN FORCE	AMOUNT RANGE (\$)
CANADIAN COMPANIES	0 - 14.34
BRITISH COMPANIES	0 - 1.22
FOREIGN COMPANIES	0.08 - 7.97
PROVISION AS % OF CAPITAL	C DANCE
AND UNAPPROPRIATED SURPLUS	<u>% RANGE</u>
CANADIAN COMPANIES	0.16 - 335.0
BRITISH COMPANIES	0.13 - 19.8
FOREIGN COMPANIES	0.06 - 78.0
PROVISION AS % OF LIABILITIES	% RANGE
CANADIAN COMPANIES	0 - 21.0
BRITISH COMPANIES	0 - 44.0
FOREIGN COMPANIES	0 - 35.0

SLIDE 7

AIDS PROVISIONS

SUPPLEMENTAL BREAKDOWNS

	NUMBER <u>REPORTING</u>	PRODUCT	PAR/ <u>NON-PAR</u>	LIFE/A&S
CANADIAN COMPANIE	S 56	17	20	8
BRITISH COMPANIES	83	4	3	2
FOREIGN COMPANIES	<u>11</u>	_11	<u>_1</u>	_0
TOTAL	150	32	24	10

METHODOLOGY

- Release of a memorandum (including specifications) requesting a special report on PPM by June 30, 1989
- Acknowledgement of receipt to each company filing a special report
- Build-up of several databases to gather and treat the information contained in the special reports
- Verification and validation of the keyed-in information
- Analysis of the reports:
 - a) Reading and analysis (review) of each report by the Actuarial Section, Life

 Division
 - b) Independent reading and analysis by a Fellow
 - c) Reading and review of (a) and (b) by a Fellow
 - d) Addressing unanswered questions on some special reports
- Preparation of a final report containing the OSFI conclusions and recommendations to the Minister based on:
 - a) Special reports
 - b) Sensitivity project

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS COMPLIANCE WITH CIA VALUATION STANDARDS

NUMBER OF VALUATION ACTUARY REPORTS: 58

	VALUATION TECHNIQUE PAPER (CIA)		OID MPLY	DID NOT COMPLY	NOT APPLICABLE	NOT DISCUSSED	
1.	LAPSE-SUPPORTED PRODUCTS	31	(70%)	5	14	8	
2.	INDIVIDUAL RENEWABLE TERM INSURANCE	41	(79%)	4	6	7	
3.	FUTURE CASH FLOW INVESTMENT ASSUMPTION FOR ORDINARY LIFE	34	(63%)	12	4	8	
4.	REINSURED POLICIES	21	(43%)	16	9	12	
5.	ADJUSTABLE PRODUCTS	17	(40%)	14	15	12	
6.	EXPECTED MORTALITY EXPERIENCE FOR INDIVIDUAL INSURANCE	45	(85%)	4	5	4	

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS PROVISION FOR ADVERSE DEVIATION (PAD)

	ACTUARIAL ASSUMPTIONS							
TREATMENT OF PAD	INTEREST	MORTALITY	LAPSE	EXPENSES				
EXPLICIT PAD WITH DETAILS	24	40	24	27				
IMPLICIT MARGINS HELD	3	4	7	3				
GENERAL STATEMENT ABOUT PAD	9	3	7	6				
NOT APPLICABLE	4	4	4	4				
NO DISCUSSION	18 13)	7 (2)	19 (14)	18 (13)				
TOTALS	58	58	58	58				

NOTE: 5 COMPANIES OMITTED TO DISCUSS ANY PROVISION FOR ADVERSE DEVIATIONS.

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS

STATUS REPORT

COMPANIES	TOTAL <u>NUMBER</u>	NUMBER OF REPORTS <u>RECEIVED</u>	NUMBER STATING NO REPORT WILL BE FILED
CANADIAN	57	43	3
BRITISH	11*	4	1
FOREIGN	82*	11	12
TOTALS	150	58	16

* Of the 19 British and foreign companies for which we requested the special reports, 13 have been received and 3 companies indicated that they would not submit a report.

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS FRONT-ENDING OF PROFITS

	TREA	TMENT OF FRONT EN	
O. OF COMPANIES		NOT DIS	
SPECIAL REPORTS	DISCUSSED	JUSTIFIED	NO MENTION
58	39	13	6
O. OF COMPANIES	NO. OF COMPANIES	NO. OF PRODUCTS	NO. OF PRODUCTS
HERE DISCUSSION	SHOWING SOME	DISCUSSED FOR	SHOWING SOME
F FRONT-ENDING	FRONT-ENDING	FRONT-ENDING OF	FRONT-ENDING OF
F PROFITS	OF PROFITS	PROFITS	PROFITS
39	16	122	29
	N	UMBER OF PRODUCT	S
		SHOWING SOME FRONT-ENDING	NOT SHOWING FRONT-ENDING
YPE OF PRODUCTS	DISCUSSED	OF PROFITS	OF PROFITS
ERMANENT	43	12	31
ERM	67	16	51
APSE-SUPPPORTED	12	1	11
TOTAL	122	29	93

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS TOTAL IMPACT ON INDIVIDUAL LIFE INSURANCE

PARTICIPATING INSURANCE

	RESERVE LIABILITIES		SURPLUS APPROPRIATIONS			TOTAL				
COMPANY		CURRENT PANY STANDARD		REDUCTION		CURRENT REDUCTION STANDARD		CURRENT REDUCTION STANDARD		CTION
SIZE	#	AMOUNT	AMOUNT		AMOUNT		PERCENT	AMOUNT	AMOUNT	PERCENT
SMALL	10	679,363	52,255	7.7	18,811	(34,389)	(182.8)	698,174	17,866	2.6
MEDIUM	16	2,827,607	318,093	11.2	68,238	(197,118)	(288.9)	2,895,845	120,975	4.2
LARGE	9	17,942,761	961,203	5.4	275,969	(652,114)	(236.3)	18,218,730	309,089	1.7
TOTAL	35	21,449,731	1,331,551	6.2	363,018	(883,621)	(243.4)	21,812,749	447,930	2.1

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS TOTAL IMPACT ON INDIVIDUAL LIFE INSURANCE

NON-PARTICIPATING INSURANCE

			RESE	RVE LIABIL	<u>ITIES</u>	SURPLU	JS APPROPRI	<u>IATIONS</u>	<u>TO</u>	<u>ΓAL</u>	
			CURRENT	REDU	CTION	CURRENT	REDU	CTION	CURRENT	REDUC	CTION
_	COMPAN	Y	STANDARD			STANDARI)		STANDARD		
<u>~</u>	SIZE	_#_	AMOUNT	AMOUNT	PERCENT	AMOUNT	AMOUNT	PERCENT	AMOUNT	AMOUNT	PERCENT
	SMALL	20	388,387	142,481	36.7	83,135	(70,585)	(84.9)	471,522	71,896	15.3
	MEDIUM	11	802,387	88,795	11.1	65,171	(45,134)	(69.3)	867,558	43,661	5.0
	LARGE	11	3,233,685	118,858	3.7	430,294	(129,171)	(30.0)	3,663,979	(10,313)	(0.3)
	TOTALS	42	4,424,459	350,134	7.9	578,600	(244,890)	(42.3)	5,003,059	105,244	2.1
	TOTAL PAR AND NON-PAR		25,874,190	1,681,685	6.5	941,618	(1,128,511)	(119.8)	26,815,808	533,174	2.1

POLICY PREMIUM METHOD JUNE 30 SPECIAL REPORTS IMPACT ON EACH LINE OF BUSINESS

RESERVE LIABILITIES					SURPLUS APPROPRIATIONS			TOTAL		
		CURRENT	REDU	CTION		REDU	CTION			CTION
LINE OF BUSINESS	_#_	STANDARD AMOUNT	AMOUNT	PERCENT	STANDARD AMOUNT	AMOUNT	PERCENT	STANDARD AMOUNT	AMOUNT	PERCENT
ORDINARY LIFE-PAR	35	21,449,731	1,331,551	6.2	363,018	(883,621)	(243.4)	21,812,749	447,930	2.1
ORDINARY LIFE NON-PAR	42	4,424,459	350,134	7.9	578,600	(244,890)	(42.3)	5,003,059	105,244	2.1
GROUP LIFE PAR	4	477,087	11,348	2.4	1,775	(5,242)	(295.4)	478,862	6,106	1.3
GROUP LIFE NON-PAR	3	77,444	6,719	8.7	1,673	(1,065)	(63.7)	69,117	5,654	7.1
INDIV. A & S	6	104,699	23,806	22.8	16,127	(18,561)	(115.1)	120,826	5,245	4.3
GROUP A & S	4	432,760	11,924	2.8	3,972	(8,166)	(205.6)	436,732	3,758	0.9
TOTALS		26,966,180	1,735,482	6.4	965,165	(1,161,545)	(120.3)	27,931,345	573,937	2.1